06.12.25 -- Billions Of Dollars In CDMO Secondary Packaging Of Biologics

With over 30+ years of experience, Catalent offers a comprehensive suite of orthogonal GMP analytical services for all biological modalities, from discovery to commercial phases. Our seasoned experts ensure exceptional on-time delivery and client satisfaction by providing tailored solutions to meet your unique needs—no matter the complexity, scale, or timeline. Watch our intro video to learn more about our capabilities!

By working with a single supplier that can handle the entire manufacturing value chain, companies can reduce risk, improve flexibility, and accelerate their time to market.

Discover five key factors that drive a seamless technology transfer, highlighting how a culture of technical expertise, customer focus, and operational flexibility is crucial to success in the CDMO industry.

Explore how fostering a strong safety culture — rooted in accountability, collaboration, and proactive risk management — can drive operational excellence and long-term success in biopharmaceuticals.

More outsourcing, but often less financing and a leaner internal staff. What's a biotech to do? Prepare carefully to outsource. Here, speakers discuss how to do that.

This presentation discusses the shift in pharmaceuticals from small-molecule drugs to protein biologics and the associated challenges, particularly the immunogenic response.

Proper formulation development has a huge impact on whether a technology transfer to the clinical phase is successful. Review the challenges of transitioning a promising drug candidate.

ADCs have proven to be highly effective in cancer treatment, but their manufacturing poses challenges. Learn how a CDMO partner can help bring these treatments to patients safely and efficiently.

Recent advancements in genetic engineering and analytical techniques have significantly enhanced E. coli's potential for protein expression.

This cell line development technology overcomes production challenges related to the scalability of complex biologics.

As biologics research expands to target new diseases with novel therapeutic constructs, innovative drug delivery devices are returning to the spotlight.

Compliance with Annex-1 is achieved through the use of robotic isolators, PUPSIT, contamination control strategies, and rigorous training to support the aseptic sterile fill-finish of early-phase clinical products.

Commercial biomanufacturing isn't static—it's an evolving process. This webinar shares real-world case studies from Lonza’s microbial manufacturing facility, highlighting how continuous improvement is achieved through data-driven yield optimization, process refinement, and deviation analysis. Attendees will learn how to maintain agility, apply Six Sigma tools, and build resilience into operations to enhance efficiency, quality, and performance. Click here to learn more.

We provide biologics development support across clinical phases, including process and formulation development, aligned with global regulatory requirements.

Advance your clinical and commercial programs with expert aseptic fill finish and formulation services across vials, cartridges, and syringes, all in state-of-the-art, EU Annex 1-compliant facilities.

Witness how proven expertise and expanding capabilities in ADC manufacturing can help you scale high-value injectable therapies with speed, quality, and regulatory confidence.

Daikyo Crystal Zenith cartridges provide predictable and safe performance with tight dimensional tolerances, utilizing a proven polymer ideal for high-viscosity drugs and long-term storage.

Here, we examine a collaboration between three industry leaders that streamlines the path from DNA to aseptic fill for ADC development.